Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc., trading under the ticker UPTD, is a clinical-stage biopharmaceutical company focused on immunology and immuno-oncology therapeutics. The company emerged from a SPAC business combination and filed an 8-K with the SEC on August 1, 2023, under accession number 0001213900-23-061514, reflecting a material corporate event. Operating in the healthcare and life sciences sector, Estrella Immunopharma targets the development of novel therapeutic candidates for immune-mediated diseases. The filing marks a notable data point in the company's post-combination disclosure history on the public markets. For complete filing history, sponsor details, and deal analytics on UPTD and hundreds of other SPAC transactions, sign up for full data access at SpacDesk.